Capsugel completes acquisition of Xcelience and Powdersize

Enhances the firm's position as a leading provider of dosage forms and solutions

Capsugel has completed its purchase of Xcelience and Powdersize, for an undisclosed sum.

The firms are now part of Capsugel's Dosage Form Solutions business unit, which designs, develops and manufactures innovative dosage forms.

The acquisitions, announced on 14 December 2015, provide Capsugel with specialised clinical trial manufacturing and supply capabilities for a broad range of solid dosage forms; development and manufacturing for specialised products such as highly potent and controlled substance compounds; and micronisation capabilities that augment the company's formulation design services and bioavailability enhancement technology platform.

The firm said that when combined with its wide array of hard capsule technologies, the expanded capabilities of Capsugel Dosage Form Solutions make the company better positioned to partner with customers to deliver innovative, patient-centric dosage forms and solutions.

Headquartered in Morristown, NJ, US, Capsugel serves more than 4,000 customers in more than 100 countries.

Companies